 |
 |
Cancer Research Studies
Treatment: Ovarian Cancer
Treatment: Ovarian Cancer
Study Title:
GOG-0218 A Phase III Trial of Carboplatin
and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus
Concurrent Bevacizumab (NSC #704865, IND #7921) Followed by Placebo, Versus
Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab,
in Women with Newly Diagnosed, Previously Untreated, STAGE III OR IV,
Epithelial Ovarian or Primary Peritoneal Cancer
What is the purpose of this study?
The purpose of this study is to evaluate new treatment regimens for
stage III and stage IV ovarian cancer.
Am I a candidate for this study?
- Were you diagnosed with stage III or IV ovarian cancer?
- Are you otherwise generally healthy?
- Have you had surgery to remove the cancer?
- Are you 18 years or older?
What do I need to do?
- Provide a medical and surgical history.
- Agree to clinical examinations that include vital signs, laboratory tests (urine, blood).
- Agree to be randomized (like a coin toss) to a particular treatment regimen.
- Agree to receive chemotherapy.
- Agree to receive a drug that is FDA approved for colon cancer, but not yet for ovarian cancer.
Why should I participate?
- Your participation can make a difference in the way ovarian cancer is being treated.
- You may receive the best possible treatment.
- There is medical need for additional treatments for stage III and IV ovarian cancer.
If you are interested in participating in this
ovarian cancer research study, please contact:
Krisin Sorensn, MS, RN, clinical research nurse
Holy Cross Hospital, Clinical Research Department
301.754.7961
sorenk@holycrosshealth.org
Principle Investigator: James Barter, MD, gynecology oncology surgeon
Co-investigators:
Cheryl A. Aylesworth, MD, medical oncologist
Kashif Firozvi, MD, medical oncologist
About Our Program
Prevention & Early Detection
Studies
Treatment Studies
Survivor Studies
Related Information